Comparative urinary metabolomics reveals unique and shared pathways in COVID-19 and liver diseases | Synapse
March 1, 2026Open Access
Comparative urinary metabolomics reveals unique and shared pathways in COVID-19 and liver diseases
Puntos clave
This research aims to explore metabolic changes in COVID-19 and liver diseases to identify unique and common pathways.
Conducted a comparative urinary metabolomics analysis
Examined metabolic profiles of COVID-19 and liver disease samples
Identified specific metabolic pathways involved
Revealed unique metabolic pathways in COVID-19
Showed shared metabolic alterations between COVID-19 and liver diseases
Identified potential biomarkers for diagnosis and treatment targeting
Resumen
These findings enhance our understanding of disease-specific metabolic remodelling and point to potential biomarkers for diagnosis and therapeutic targeting.